A biologist by the name of Stephen Austad placed a wager back in 2000. He bet that the first person to live to be 150 years old was already on the planet, having been born, breathing, and aging through whatever stage of childhood or middle age they were in at the time. Based at the University of Alabama at Birmingham, Austad researches the biology of aging.
According to most accounts, he is not the kind of person who makes snap judgments. The wager, which was made with a coworker, was designed to pay out in 2150. He might be correct. That’s not a comfortable thought; rather, it’s a genuinely strange one that, depending on how you feel about time passing, falls somewhere between exciting and a little unsettling.
What has occurred in research labs over the past few years, particularly in 2025, which proved to be one of the more productive years in the relatively young science of human longevity, makes Austad’s confidence less ludicrous than it sounds. Human clinical trials, drug repurposing studies, metabolic research, and gradually changing regulatory attitudes—all of which would have seemed improbable ten years ago—all contributed to breakthroughs. The picture that is being pieced together shows aging as a biological process with recognizable levers rather than as an inevitable and fixed endpoint. It turns out that some of those levers are already accessible.
Rapamycin is the medication that keeps coming up at the center of all of this. It was first created as an immunosuppressant for organ transplant recipients, found in soil samples from Easter Island in the 1970s, and is now subtly emerging as one of the most researched molecules in the field of longevity. Since it began conducting systematic trials in 2004, the National Institute on Aging’s Interventions Testing Program has tested 54 compounds using a variety of mouse models at several separate locations.
Rapamycin continues to be the most reliable lifespan-extending medication for both sexes. On its own, it increased lifespan in mice by about 15 to 20 percent; when paired with the diabetes medication acarbose, the median lifespan extension increased to 36.6 percent. It’s difficult to read that number without pausing. a consistently replicated 36% increase in median lifespan. That level of consistency is unattainable with any single-molecule cancer treatment.
Naturally, the transition from mice to humans is where science becomes intricate, cautious, and slow. On that front, however, 2025 brought something truly significant. The PEARL trial, a 48-week double-blind randomized study in adults roughly between the ages of 50 and 85, looked at the effects of weekly low-dose rapamycin in healthy individuals who were just getting older and not ill or experiencing a crisis. While not revolutionary in every metric, the results were encouraging in significant ways.
In comparison to baseline, lean tissue mass increased by 6% in women receiving the higher 10 mg dose. Pain, emotional health, and overall health all showed improvements in self-reported scores. Crucially, there was no discernible rise in serious adverse events when compared to a placebo, and the safety profile held up. That is important information, not merely a footnote, for a medication that has been linked for decades to immune suppression and severe side effects.
It’s difficult to ignore how much the topic of discussion has changed from “can we slow aging” to “which combination of interventions works best and for whom.” Although subtle, that shift in framing is significant. The previous approach was reactive, treating illness after it manifests. Quietly, the longevity research community is working toward something more proactive: changing the biological mechanisms that initially increase the likelihood of disease.
According to ITP data, SGLT2 inhibitors—which were first created to treat type 2 diabetes—improved male mouse longevity by 13.6%. GLP-1 medications, which are currently well-known for their ability to help people lose weight, are being investigated for their wider metabolic and potentially aging-related effects. In 2025, the FDA eliminated its long-standing black box warning on hormone replacement treatments, a regulatory indication that institutional perspectives on proactive longevity interventions are gradually, cautiously, but noticeably changing.
How much of this directly relates to human biology over the course of a lifetime is still genuinely unknown. Humans are not mice, even though mouse models are helpful and the ITP’s methodology is as rigorous as this type of research gets. We all age differently, have varying disease burdens, and live in environments that are impossible to completely replicate in a lab.
There are actual data gaps. In a late 2025 report on the state of longevity science, Fortune magazine pointed out that while AI is increasingly being used to help find patterns in massive biological datasets that human researchers would overlook, the field still has a lot to learn about aging in a variety of human populations. Some of the things that work so well in controlled animal experiments might prove to be more difficult in the wild variations of human life. Even though the optimism is undoubtedly growing, it is worthwhile to cling to that uncertainty.
A generation of researchers, many of whom work in labs in Boston, San Francisco, and London, were raised to believe that aging was just a natural part of life and that medicine’s role was to control its effects. Unlike earlier waves of anti-aging enthusiasm, which tended to rely heavily on supplements, calorie restriction, and anecdotes, this assumption is being questioned in a way that feels qualitatively different. The institutional weight behind it—the NIA, significant clinical trials, peer-reviewed publications, and a cautious but genuine regulatory movement—has changed.
A breakthrough is not assured by that combination. However, it does imply that the way science approaches the issue is actually evolving. It remains to be seen if Stephen Austad will profit from his wager in 2150. However, current research is beginning to resemble the preliminary stages of something tangible rather than merely conjecture.
